At Sarepta Therapeutics we develop first-in-class RNA-based therapies to improve and save the lives of people affected by life-threatening diseases.

Our rapidly advancing clinical programs have positioned us on the threshold of fully realizing the potential of our differentiated RNA-based technology. These include our lead clinical candidate, eteplirsen, for the treatment of Duchenne muscular dystrophy, and potential treatments for the lethal hemorrhagic fever viruses, Ebola and Marburg.

Learn more about Sarepta Therapeutics and the transformative potential of our RNA-based technology for patients who face significant unmet medical needs.